A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen TDS-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects

Trial Profile

A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen TDS-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Acronyms TRANSFERENCE
  • Sponsors Transdermal Delivery Solutions Corp
  • Most Recent Events

    • 18 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
    • 18 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 04 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top